Financial Review has been sticking the boot into RCR every story . It’s been right all along mind you .
Meanwhile I think I agree with Oscar09 ...”wait and see” ( not that I have an alternative)
RCR market cap now only $231 million.
Was the market genuinely expecting the order book of $1.07 billion to be sitting patiently in the wings ?
No the market is not naive so it was not expecting the order book to be as good as was touted at AGM.
So RCR - to me - seems to be priced according to low realities, not pie in sky projections.
As a comparison NRW Holdings has an order book of $2.2 billion, about the same in cash, and market cap is currently scandalously low at $683 million
Maca has an order book of $1.28billion, expects earnings of $620million FY2019, market cap of $322.9 million.
I know it is not a level playing field but if those companies are undervalued where does that put RCR?
Worst case scenario?
The last time I saw one of these it was because the material impact was 40% greater than expected.
Reversing this, in a (hopefully) worse case scenario the RCR update will not put earnings forecast worse than 40% lower than anticipated?
This would reduce the earnings forecast to $600 odd million
So what will they do?
Another round of funding this time at 77c?
Outcome?
Is this the opportunity for a theoretical buyer to take an initial stake really cheaply then buy shares from Alan Gray etc to increase it’s position prior to takeover?
If I wanted the company that is how I would play it ...
But maybe nobody wants RCR after all?
Personally I find it quite unlikeable even though I still think it is good value at these prices
Cheers
- Forums
- ASX - By Stock
- RCR
- Ann: Trading Halt
RCR
rincon resources limited
Add to My Watchlist
0.00%
!
1.2¢

Ann: Trading Halt, page-12
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.510M |
Open | High | Low | Value | Volume |
1.2¢ | 1.2¢ | 1.2¢ | $9.738K | 811.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 2991811 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 32500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 2991811 | 0.011 |
4 | 1622323 | 0.010 |
4 | 402222 | 0.009 |
3 | 480000 | 0.008 |
2 | 271430 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 32500 | 1 |
0.013 | 772000 | 2 |
0.014 | 1326174 | 5 |
0.016 | 276029 | 2 |
0.019 | 35117 | 1 |
Last trade - 14.57pm 27/06/2025 (20 minute delay) ? |
Featured News
RCR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online